Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept

Annals of the Rheumatic Diseases

Volumn 62, Issue 6, 2003, Pages 561-564

  Zou, J ^a   Rudwaleit, M ^a   Brandt, J ^a   Thiel, A ^b   Braun, J ^a,c   Sieper, J ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatology Research Centre   (Germany)

^c Rheumazentrum Herne ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; CD4 ANTIGEN; CD8 ANTIGEN; ETANERCEPT; GAMMA INTERFERON; PEPTIDE; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; MACROPHAGE; MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIRHEUMATIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN G; INTERFERON TYPE II; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0037809605     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.6.561     Document Type: Article

References (16)

1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
2. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
3. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90.
4. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
5. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
6. Braun J, Brandt J, Listing J, Zink A, Alten R, Krause A, et al. Treatment of active ankylosing spondylitis with infliximab - a double-blind placebo controlled multicenter trial. Lancet 2002;359:1187-9
7. Gorman JD, Sack KE, Davis JC. Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheum 2000;43(suppl):S403
8. Brandt J, Kariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, et al. Six month results of a double-blind placebo controlled treatment trial of etanercept in patients with active ankylosing spondylitis. Arthritis Rheum (in press).
9. Thiel A, Wu P, Lauster R, Braun J, Radbruch A, Sieper J. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum 2000;43:2834-42.
10. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
11. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors. Ann Rheum Dis 2001;60:133-9.
12. Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα. Ann Rheum Dis 2001;60:750-5.
13. Zou JX, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Downregulation of the non-specific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003;48;780-90.
14. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002;359:1541-9.
15. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
16. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;346:623-6.